DOCSLIB.ORG

Proquest Dissertations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Proquest Dissertations INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may t>e from any type of computer printer. The quality of this reproduction is dependent upon tfie quality of the copy submitted. Broken or indistmct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event tfiat the author did not send UMI a complete manuscript and there are missing pages, these will t>e noted. Also, if unauthorized copyright material had te be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, t>eginning at the upper left-hand comer and continuing from left to right in equal sections with small overlaps. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6” x 9” black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. Bell & Howell Information and Learning 300 North Zeeb Road, Ann Arbor, Ml 48106-1346 USA UIVLI800-521-0600 ENHANCED IN VIVO AND IN VITRO RESPONSE TO BETA-2 ADRENERGIC RECEPTOR STIMULATION IN ANIMALS SUSCEPTIBLE TO VENTRICULAR FIBRILLATION DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Melanie Taghon Houle, M.S. ***** The Ohio State University 1999 Dissertation Committee: Approved By Professor George E. Billman, Adviser Professor Ruth A. Altschuld Professor Patrick Ward Professor Jack Rail Adviser Graduate Program in Physiology UMI Number: 9951667 UTVLI 9951667 Copyright 2000 by Bell & Howell Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. Bell & Howell Biformation and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ABSTRACT Sudden, cardiac death is an unexpected natural death from a cardiac cause within a short period of time from the onset of symptoms. A canine model of sudden cardiac death has been developed such that dogs with a healed myocardial infarct (MI) develop ventricular fibrillation (VF) induced by a 2 min coronary occlusion during the last min of exercise and maintained one min after exercise. An enhanced (3%-adrenergic receptor (P 2- AR) response was noted in dogs that were susceptible to VF. It was previously demonstrated that the pz-AR agonist zinterol elicited larger increases in the transient amplitude in myocytes obtained from susceptible (S) as compared to resistant (R) dogs. The contractile response to Pz-AR stimulation had not been determined in the intact animal. Therefore, the contractile response to P-adrenergic receptor (p-AR) stimulation was evaluated using echocardiography (velocity o f circumferential fiber shortening (Vcf) both before (n=35, S=19 & R=16) and after anterior wall infarction (MI, n=31, S=12 & R=19). Before MI, increasing doses of isoproterenol (ISO) provoked similar responses in both groups of dogs. The Pi-adrenergic receptor (Pi-AR) or Pz-AR antagonists (bisoprolol or ICI 118,551 respectively) had similar effects on the ISO response in both groups with a larger reduction noted after Pi-AR blockade. In contrast, after Ml, the susceptible dogs displayed a significantly (ANOVA p<0.01) larger Vcf response to ISO which was eliminated by both Pa-AR and Pi-AR blockade. The single cell unloaded shortening response to ISO was also larger in cells obtained from susceptible animals as compared to resistant dogs. As was noted in the intact animal, the Pa-AR antagonist ICI 118,551 elicited a greater reduction in the susceptible dog myocytes (S, -48%, n = 6 and R, -15%, n=9). The number o f Pa-ARs, as determined by radioligand binding, as well as the Kd value, was similar in both groups. As such, these data suggest that the enhanced Pa-AR response provoked by infarction in the susceptible dogs may result from altered Pa-AR coupling to G proteins resulting in cytosolic Ca“^ changes. The p44/42 mitogen activated protein (MAP) kinase cascade is coupled to a Gi protein and has been implicated as a possible alternative non-arrhythmogenic signaling pathway for the Pa-AR. Therefore, the hypothesis that the resistant animals activate the p44/42 MAP kinase pathway while the susceptible animals activate the Gs/cAMP pathway was explored. With Pa-AR as well as a i-adrenergic receptor (ai-AR) activation, the susceptible animals (n= 6 ) had a significantly greater upregulation of the p44/42 MAP kinase pathway as compared to the resistant animals (n= 6 ). Therefore, preferential activation of the p44/42 MAP kinase system cannot explain the observed differences in susceptibility to ventricular fibrillation. However, the possibility still exists for stronger coupling to the Gs protein of the cardiac pz-AR in susceptible animals thereby contributing to abnormalities in calcium handling in these animals. Ill DEDICATION “There are no secrets to success: Don’t waste time looking for them. Success is the result of perfection, hardwork, learning from failure, loyalty to those with whom you work and persistence.” General Colin Powell I would like to dedicate this thesis to my husband, Tom, who never let me give up, and to my son, Sam, who never let me forget what is truly important. IV ACKNOWLEDGMENTS I wish to thank my adviser. Dr. George Billman, for many years of support and understanding as well as his patience in guiding me through the formation of this dissertation. I would also like to thank Dr. Ruth Altschuld for the insightfid conversations, guidance and encouragement through the (at times) exasperating single cell and MAP kinase experiments. 1 am grateful for the technical help and encouragement of Lou Castillo who helped with the myocyte isolation procedure. Bob Kelley for help with the edge detection studies. Dr. Tomohiro Nakayama for his expert echocardiography skills, and Dr. Beth Holycross for her insightful conversations. I would also like to thank my husband, Tom Houle, for his expert computer assistance. Finally, I must acknowledge the generous contributions of Merck Parmaceutical for supplying the bisoprolol as well as Proctor and Gamble for supplying some of the susceptible animals used for the single cell and MAP kinase studies. VITA September 8 , 1968 .......................................................Bom - South Bend, Indiana May 1990 ..................................................................... B.S. Biology, Saint Mary’s College, South Bend, Indiana 1990-1992 ...................................................................AT.S. Biology, University o f Denver. Denver, Colorado 1992-1994 .....................................................................Instructor, Chemistry University of Nebraska, Omaha Omaha, Nebraska 1995-present .................................................................Graduate Research Associate The Ohio State University Columbus, Ohio PUBLICATIONS 1. Taghon, M. S. and S.E. Sadler, Insulin-like growth factor 1 receptor mediated endocytosis in Xenopus laevis oocytes: A role for receptor tyrosine kinase activity. Developmental Biology 163(l):66-74, 1994. 2. Houle, M. S. and G. E. Billman. Low frequency component of the heart rate variability spectrum: a poor marker of sympathetic activity. Am J Physiol. 276(Heart Circ. Physiol. 45)H215-H223, 1999 3. Lynch, J. J., M. S. Houle, G. L. Stump, A. A. Wallace, D. B. Gilberto, H. Jahansouz, G. R. Smith, A. J. Tebbens, N. J. Liverton, H. G. Seinick, D. A. Claremon, and G. E. Billman. Antiarrhythmic efficacy of selective blockade o f the cardiac slowly activating delayed rectifier current Iks in canine models of malignant ischemic ventricular arrhythmias. Circulation 1999;100:1917-1923. VI ABSTRACTS 1 . Houle, M. S. and G. E. Billman. The autonomic response to exercise in animals susceptible to ventricular fibrillation. Physiologist 39: A17, 1996. 2. Houle, M. S., G. E. Billman, and P. Ward. In Vivo biological activities of angiotensin and kinin metabolites in dog vasculature. FASEB /II: A501, 1997. 3. Billman, G. E. and M. S. Houle. Heart rate variability in animals susceptible to ventricular fibrillation: low firequency power is a poor marker of sympathetic activity. JAuton Nerv Sys 65: 87, 1997. 4. Houle, M. S., G. E. Billman, J. Hensley, and R. A. Altschuld. Effects of calcium channel antagonists on Ca^^ transients in canine atrial cardiomyocytes. FASEB J 12: A74, 1998. 5. Billman, G. E., M. S. Houle, and J. J. Lynch. Selective Iks blockade protects against ventricular fibrillation induced by myocardial ischemia. Enr Heart J 19(Abstract Suppl): 17, 1998. 6 . Houle, M. S., L. Castillo, J. Hensley, C. M. Hohl, P. F. Binkley, R. A. Altschuld, and G. E. Billman. Enhanced in vivo response to Pi-adrenergic receptor activation in post- infarcted canines susceptible to ventricular fibrillation. Circulation 98:1-553, 1998. 7. Billman, G. E., M. S. Houle, and J. J. Lynch. Selective Iks, but not Ikt blockade protects against ventricular fibrillation induced by myocardial ischemia. Circulation 98: 1-52, 1998. 8 . Houle, M. S., T. Nakayama, R. A. Altschuld, and G. E. Billman. Enhanced in vivo and in vitro contractile responses to Pa-adrenergic
Load more

Recommended publications
  • Modulation of Dialysate Levels of Dopamine, Noradrenaline
    Modulation of Dialysate Levels of Dopamine, Noradrenaline, and Serotonin (5-HT) in the Frontal Cortex of Freely-Moving Rats by (-)-Pindolol Alone and in Association with 5-HT Reuptake Inhibitors: Comparative Roles b of -Adrenergic, 5-HT1A, and 5-HT1B Receptors Alain Gobert, Ph.D. and Mark J. Millan, Ph.D. (-)-Pindolol, which possesses significant affinity for 5-HT1A, involved. (-)-Pindolol potentiated the increase in FCX levels b 5-HT1B, and 1/2-adrenergic receptors (AR)s, dose- of 5-HT elicited by the 5-HT reuptake inhibitors, fluoxetine dependently increased extracellular levels of dopamine and duloxetine, and also enhanced their ability to elevate (DA) and noradrenaline (NAD) versus 5-HT, in dialysates FCX levels of DA—though not of NAD. In contrast to of the frontal cortex (FCX), but not accumbens and (-)-pindolol, betaxolol and ICI118,551 did not affect the striatum, of freely-moving rats. In distinction, the actions of fluoxetine, whereas both WAY100,635 and b preferential 1-AR antagonist, betaxolol, and the SB224,289 potentiated the increase in levels of 5-HT—but b preferential 2-AR antagonist, ICI118,551, did not increase not DA or NAD levels—elicited by fluoxetine. In basal levels of DA, NAD, or 5-HT. Further, they both dose- conclusion, (-)-pindolol modulates, both alone and together dependently and markedly blunted the influence of with 5-HT reuptake inhibitors, dopaminergic, adrenergic, (-)-pindolol upon DA and NAD levels. The selective 5-HT1A and serotonergic transmission in the FCX via a complex b receptor antagonist, WAY100,635, slightly attenuated the pattern of actions at 1/2-ARs, 5-HT1A, and 5-HT1B (-)-pindolol-induced increase in DA and NAD levels, while receptors.
    [Show full text]
  • G Protein‐Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
    [Show full text]
  • American Heart Association Preview 2017.Pdf
    NovemberNovember 11-15 11-15 Anaheim,Anaheim, California California PREVIEWTHE IN CLASS CARDIOVASCULAR CONFERENCE EDUCATIONAL SESSIONS FOR ALL CAREER STAGES WITH GLOBAL THOUGHT LEADERS innovative FACULTY PROVIDING INTERACTIVE, network PERSONALIZED EDUCATION world- renowned PAID ADVERTISEMENT PICK UP A FREE COPY AT: AHA HeartQuarters, booth #355 Wolters Kluwer, booth #439 Wiley, booth #545 FIND THE ENTIRE AHA /ASA JOURNALS’ TREND WATCH COLLECTION ONLINE DOWNLOAD ALL 3 ISSUES TODAY! Freely 450+ Available Articles INTERACTIVE MAGAZINE DOWNLOAD THE BLIPPAR APP App required for free, full-text Download the latest issue and view access to Trend Watch. a video demonstration at AVAILABLE ON www.ahajournals.org/site/trendwatch American Heart Association American Heart Association National Center 7272 Greenville Ave. Dallas, TX 75231 214-373-6300 800-242-2453 professional.heart.org Registration INSIDE Convention Data Services 107 Waterhouse Road THE PREVIEW Bourne, MA 02532 800-748-3583 (inside U.S.) 508-743-8517 (outside U.S.) Join the [email protected] AHA Scientific Sessions 2017 conversation Housing 2 Welcome from the program chair onPeak 4 What’s hot at AHA Scientific Sessions 2017 381 Park Ave. S., Third Floor 6 Expect the best in 2017 New York, NY 10 Week at a glance facebook.com/ 800-221-3531 (inside U.S.) ahameetings 312-527-7300 (outside U.S.) [email protected] Advance programming and faculty Facility Anaheim Convention Center 14 Programming information and schedule @AHAmeetings 800 W. Katella Ave. #AHA17 Anaheim, CA 92802 14 CE/CME
    [Show full text]
  • Cap11 Adrenolitico
    SECCION II: CAPITULO 11 DROGAS SIMPATICOLITICAS O ADRENOLITICAS Malgor - Valsecia Como anteriormente se mencionara, el siste- Son un grupo de drogas que actúan en la ter- ma Simpático o Adrenérgico cumple num ero- minación adrenérgica, a nivel axoplasmático o sas e importantísimas funciones biológicas sobre receptores presinápticos alfa2, salvo indispensables para la modulación y regula- estos últimos agentes, los adrenolíticos presi- ción de organismos y sistemas que son vitales nápticos tienen ac tualmente un uso clínico para el mantenimiento de una vida normal. terapéutico limitado. CLASIFICACIÓN DE DROGAS SIMPATICO- Las drogas simpaticolíticas o adrenolíticas LÍTICAS son un grupo numeroso de fármacos que in- terfieren con las funciones del sistema simpá- I.SIMPATICOLITICOS PRESINAPTICOS. tico, las mismas actúan básicamente de dos maneras diferentes: a.Axoplasmáticos: I- Inhiben la liberación de las catecolaminas en *Reserpina (Serpasol) la terminación adrenérgica, actuando a nivel Deserpidina presináptico y Rescinamina Guanetidina (Ismelin) II- Bloquean los receptores adrenérgicos en Batanidina las células efectoras a nivel postsináptico. Debrisoquina (Declinax,Sintiapress) Bretilio Las primeras son drogas simpaticolíticas que IMAO:Pargilina (Eutonil;Tranilcipromina (Parna- inhiben la síntesis de catecolaminas. Interfie- te) ren con los proceso de depósito y liberación de las mismas. Algunas actúan a nivel central reduciendo la activi dad simpática cerebral. b.Agonistas alfa 2:(Adrenoliticas de accion Este grupo de fármacos son los llam ados central) Simpaticolíticos presinápticos. Los simpati- colíticos postsinápticos son los bloqueantes Clonidina (Catapresan) de los receptores alfa y beta adrenérgicos. *Alfa-metil-dopa (Aldomet) Guanabenz (Rexitene) Todos estos agentes adrenolíticos son drogas Guanfacina (Estulic,Hipertensal) de gran utilidad terapéutica, capaces de gene- rar una solución farmacológica a numerosos padecimientos clínicos, principalmente en el II.SIMPATICOLITICOS POSTSINAPTICOS área cardiovascular.
    [Show full text]
  • New Concepts in Pharmacological Efficacy at 7TM Receptors: IUPHAR
    British Journal of DOI:10.1111/j.1476-5381.2012.02223.x www.brjpharmacol.org BJP Pharmacology Dr Terry Kenakin, University of International Union of Basic North Carolina, Pharmacology, Chapel Hill, North Carolina, and Clinical Pharmacology United States, Phone: 919-962-7863, Fax: 919 966 7242 Review or 5640, [email protected] ---------------------------------------------------------------- Keywords receptor theory; agonism; New concepts in efficacy; drug discovery ---------------------------------------------------------------- Received pharmacological efficacy at 8 May 2012 Revised 3 August 2012 7TM receptors: IUPHAR Accepted Review 2 12 September 2012 This is the second in a series of reviews written by committees Terry Kenakin of experts of the Nomenclature Committee of the International Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, Union of Basic and Clinical USA Pharmacology (NC-IUPHAR). A listing of all articles in the series and the Nomenclature Reports from IUPHAR published in Pharmacological Reviews can be found at http://www. GuideToPharmacology.org. This website, created in a The present-day concept of drug efficacy has changed completely from its original collaboration between the British Pharmacological Society description as the property of agonists that causes tissue activation. The ability to (BPS) and the International visualize the multiple behaviours of seven transmembrane receptors has shown that Union of Basic and Clinical drugs can have many efficacies and also that the transduction of drug stimulus to Pharmacology (IUPHAR), various cellular stimulus–response cascades can be biased towards some but not all is intended to become a pathways. This latter effect leads to agonist ‘functional selectivity’, which can be “one-stop shop” source of favourable for the improvement of agonist therapeutics.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Omega-3 Fatty Acids and Their Role in Cardiac Arrhythmogenesis Workshop Research Challenges and Opportunities
    National Heart, Lung, and Blood Institute and the Office of Dietary Supplements National Institutes of Health Omega-3 Fatty Acids and their Role in Cardiac Arrhythmogenesis Workshop Research Challenges and Opportunities August 29-30, 2005 Embassy Suites Hotel at the Chevy Chase Pavilion 4300 Military Road, NW Washington, District of Columbia 20015 AGENDA Omega-3 Fatty Acids and their Role in Cardiac Arrhythmogenesis Workshop: Research Challenges and Opportunities Day 1: Monday, August 29, 2005 9:00 a.m. Call to Order 9:30 a.m. Welcome and Opening Remarks Dr. David Lathrop Dr. Rebecca Costello 9:35 a.m. Workingshop Goals and Objectives Dr. Barry London (Chair) Session I - Background: Evidence for Antiarrhythmic Effects of Omega-3 (n-3) Fatty Acids 9:50 a.m. Evidence for Antiarrhythmic Effects from Epidemiologic Dr. Christine Albert Studies 10:20 a.m. Agency for Healthcare Research and Quality Dr. Ethan Balk (AHRQ): Evidence Reports on the Cardiovascular Ms. Mei Chung Effects of n-3 Fatty Acids 10:50 a.m. Discussion All Participants 11:05 a.m. Break . Session II –NHLBI-supported Trials to Determine the Antiarrhythmic Effects of n-3 Fatty Acids 11:15 a.m. The Fatty Acid Antiarrhythmia Trial (FATT) (R01 Dr. Alexander Leaf HL062154) 11:55 a.m. The Antiarrhythmic Effects of n-3 Fatty Acids Study (R01 Dr. John McAnulty HL061682) 12:35 p.m. Discussion All Participants 12:50 p.m. Lunch Session III – Possible Basic Mechanisms of Action 1:50 p.m. Dietary Source of n-3 Fatty Acids: Metabolic Pathways Dr. Bill Lands and Sites of Interaction 2:20 p.m.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Remodeling of Myocardial Passive Electrical Properties: Insights Into the Mechanisms of Malignant Arrhythmias and Sudden Cardiac Death
    Remodeling of Myocardial Passive Electrical Properties: Insights into the Mechanisms of Malignant Arrhythmias and Sudden Cardiac Death. DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Carlos Luis del Rio, M.S. Graduate Program in Electrical and Computer Science The Ohio State University 2015 Dissertation Committee: Professor Bradley D. Clymer, Ph.D., Advisor Professor George E. Billman, Ph.D., Co-Advisor Professor Furrukh S. Khan, Ph.D. Copyright by Carlos Luis del Rio 2015 Abstract Despite extensive research, sudden cardiac death (SCD) resulting from ischemia-induced malignant arrhythmias, such as ventricular fibrillation (VF), remains a leading cause of death, particularly following myocardial infarction (MI). Furthermore, SCD is generally the first and most common manifestation of the disease, as current risk-stratifying tools are inaccurate and insufficient. Acute/chronic changes in the passive electrical properties governing electrotonic coupling in the myocardium have been proposed as a potential mechanism mediating both the onset and maintenance of arrhythmias, as the loss of homogenizing electrotonic coupling can exacerbate intrinsic pro-arrhythmic electrical heterogeneities within the ventricle, especially during repolarization. However, no study to date has assessed the ability of indices reflective of electrotonic changes to stratify intrinsic arrhythmic susceptibility in vivo. Leveraging a well-established in vivo post-MI canine model of SCD and lethal arrhythmias, this research work investigates the pro-arrhythmic role of changes in the passive electrical properties of the myocardium, as measured by its complex electrical impedance spectrum (MEI). The studies were performed under the general hypothesis that the loss of electrotonic coupling accompanies and facilitates the development of malignant arrhythmias in the setting of ischemia and post-MI ventricular/autonomic remodeling.
    [Show full text]
  • Research Digest
    ERD Examine.com Research Digest Issue 7 ◆ May 2015 1 Table of Contents 05 Going nuts over infant peanut exposure Randomized trial of peanut consumption in infants at risk for peanut allergy 13 How the Food Industry Spins Science to Fit Its Agenda By Andy Bellatti, MS, RD 16 Non-celiac gluten sensitivity: much ado about something? Small Amounts of Gluten in Subjects with Suspected Nonceliac Gluten Sensitivity: a Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial 23 Baby probiotics for prevention of ADHD and Asperger’s A possible link between early probiotic intervention and the risk of neuropsychiatric disorders later in childhood: a randomized trial 31 Putting the “D” in Death A reverse J-shaped association between serum 25- hydroxyvitamin D and cardio- vascular disease mortality – the CopD-study 40 Eggcellent Eggs: Is it safe for people with diabetes to eat a lot of eggs? The effect of a high-egg diet on cardiovascular risk factors in people with type 2 dia- betes: the Diabetes and Egg (DIABEGG) study—a 3-mo randomized controlled trial 46 Do BCAAs and arginine prevent central fatigue during exercise? Branched-chain amino acids and arginine improve performance in two consecutive days of simulated handball games in male and female athletes: a randomized trial 52 HMB-elly be gone β-Hydroxy-β-methylbutyrate (HMB) supplementation and resistance exercise sig- nificantly reduce abdominal adiposity in healthy elderly men 58 Spicing up your workout Curcumin supplementation likely attenuates delayed onset muscle soreness (DOMS) 65 INTERVIEW: Shawn Wells, MPH, RD 71 Ask the Researcher: James Heathers, Ph.D.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Relengthening RT50, Fig 3C-G)
    Neuronal Nitric Oxide Synthase Signaling Contributes to the Beneficial Cardiac Effects of Exercise DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Steve R. Roof Biomedical Sciences Graduate Program The Ohio State University 2012 Dissertation Committee: Dr. Mark T. Ziolo, PhD Advisor Dr. George E. Billman, PhD Dr. Sandor Gyorke, PhD Dr. Brandon Biesidecki, PhD ABSTRACT Exercise is beneficial to one’s health, reduces the risk of cardiomyopathies, and is utilized as a therapeutic intervention after disease [2-7]. This is due, in part, due to the beneficial chronic adaptations that enhance contraction and accelerate relaxation [8]. These intrinsic exercise-induced adaptations are observed at the level of the cardiomyocyte [9]. That is, ventricular myocytes from exercised (Ex) mice exhibit increased Ca2+ cycling and contraction-relaxation rates [6, 9-12]. Additionally, cardiac growth (physiological hypertrophy) and an increase in aerobic fitness (VO2max) are hallmark cardiac adaptations due to exercise training. The molecular mechanisms that explain how the heart adapts are not fully understood and studies examining signaling pathways are limited. A signaling molecule with a potential role in cardiac adaptations to exercise is nitric oxide (NO). Nitric Oxide (NO) has been shown to be a key regulator of myocyte contractile function. NO, produced via the neuronal nitric oxide synthase (nNOS or NOS1), enhances basal contraction by increasing Ca2+ cycling through the sarcoplasmic reticulum (SR) [13-15]. Data suggest that NOS1 signaling increases Ca2+ uptake by targeting the SR Ca2+ ATPase (SERCA2a)/phospholamban (PLB) complex. NOS1 signaling also targets the SR Ca2+ release channel (ryanodine receptor - RYR2) to increase its open time probability [16].
    [Show full text]